Vapotherm (NYSE:VAPO) had its price objective cut by Canaccord Genuity Group from $41.00 to $35.00 in a research report issued to clients and investors on Thursday, Stock Target Advisor reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 103.61% from the stock’s current price.
Other research analysts have also issued reports about the company. Canaccord Genuity Group reduced their price target on Vapotherm from $41.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday. BTIG Research reaffirmed a “buy” rating and set a $45.00 target price on shares of Vapotherm in a research report on Monday, September 27th. Finally, Zacks Investment Research lowered Vapotherm from a “buy” rating to a “hold” rating in a research report on Tuesday, October 26th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $34.80.
VAPO opened at $17.19 on Thursday. The firm has a market cap of $448.19 million, a price-to-earnings ratio of -7.61 and a beta of -1.33. The company has a current ratio of 3.46, a quick ratio of 2.76 and a debt-to-equity ratio of 0.50. Vapotherm has a 12 month low of $16.64 and a 12 month high of $38.46. The stock has a fifty day moving average price of $21.20 and a 200-day moving average price of $23.23.
In other news, SVP Gregoire Ramade sold 2,000 shares of the stock in a transaction dated Thursday, November 4th. The stock was sold at an average price of $25.03, for a total value of $50,060.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 12.80% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in VAPO. OLD Mission Capital LLC acquired a new position in shares of Vapotherm in the third quarter valued at about $357,000. Advisor Group Holdings Inc. boosted its stake in shares of Vapotherm by 110.5% in the second quarter. Advisor Group Holdings Inc. now owns 1,987 shares of the company’s stock worth $47,000 after buying an additional 1,043 shares during the last quarter. Swiss National Bank boosted its stake in shares of Vapotherm by 7.2% in the second quarter. Swiss National Bank now owns 34,100 shares of the company’s stock worth $806,000 after buying an additional 2,300 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Vapotherm by 4.4% in the second quarter. Sei Investments Co. now owns 32,737 shares of the company’s stock worth $774,000 after buying an additional 1,394 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its stake in shares of Vapotherm by 58.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 13,392 shares of the company’s stock worth $317,000 after buying an additional 4,937 shares during the last quarter. 70.41% of the stock is currently owned by institutional investors and hedge funds.
Vapotherm Company Profile
Vapotherm, Inc is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. Its products include Precision Flow, Precision Flow Heliox, Oxygen Assist Module, Nitric Oxidie Disposable Patient Circuit, Tracheostomy Adapter, and Aerogen Adapter.
Featured Article: What is a Real Estate Investment Trust (REIT)?
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.